Event in Progress:
Discover the latest content that has just been published on Research Tree
Companies: FOG TSTL EXR
Cavendish
Tristel has reported results for the 6-months to December 2023, noting ‘record performance on all levels’. Revenue for the period grew 20% YoY to £20.9m supported by both volume and price. Gross margin improved to c84% for H1/24A from 81% in H1/23A, and though investment in employees (including new hires) saw increased SG&A expenses, adjusted EBITDA grew 18% YoY to £5.4m at a margin of 26%. Tristel is proposing a dividend of 5.24p, doubling the previous interim dividend and reflecting the compan
Companies: Tristel Plc
23nd January 2024 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obje
Companies: BCOW OMI TIDE TSTL VAST IKA VEL EMAN YU/ ECR 688536 BCOW
Hybridan
Companies: OHT TIDE ELCO TSTL VEL BBSN
The Hardman & Co Healthcare Index (HHI) has been running since 2009. Its main function is to highlight the attractions of life sciences investments over the long term. For the second year running, apart from global economic influences affecting world markets, performance in 2023 was dented by the capital-intensive nature of the sector. The HHI fell 3.7%, to 483.8, underperforming the main London markets – FTSE 100 (+3.8%) and FTSE All-Share (3.8%) but outperforming the FTSE AIM All-Share Index (
Companies: TXG NDVA TSVT BCOW Z29 TXG NCYT GNS SUN AMS OMG APH EKF EAH IMM AGL DEMG AGY TSTL IPO GDR ETX TRX HVO CTEC AVO OXB DEST VLG IXI VAL INDV AGR AVCT BAI 123F IMCR BCOW
Hardman & Co
Companies: CPX FTC TSTL TIME EXR LINV
Companies: SCE TSTL BOOM ATG
Tristel’s FY 2023 results were in-line with the July trading update, with revenues of £36.0m (+16% or 22% for continuing operations) and adjusted pre-tax profit of £6.2m (+36%, vs. Cav £6.0m), resulting in 41% adj. EPS growth (helped by lower tax charge). We leave adj. PBT for FY 2024E unchanged at £7.6m (+24%), although increase adj. EPS by 11%, due to a lower tax charge, and introduce FY 2025 forecasts, calling for adj. PBT and adj. EPS of £10.0m (+31%) and 16.5p (+20%), respectively; driven i
4th September 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment obj
Companies: TXG LEX TXG CTL AGL SAR TSTL PYC TRR AREC
Companies: DSCV IGP TSTL
Joiners: No joiners today. Leavers: No leavers today. What’s cooking in the IPO kitchen?** Announced ITF 12 July: Substrate Artificial Intelligence, an artificial intelligence company based in Spain that creates, buys and scales companies around AI in diverse sectors such as fintech, agritech, energy, human resources, and health, intends to join the Access Segment of the AQSE Growth Market. Announced ITF 6 July: Blackpoint Biotech plc, a medical cannabinoids company established to fulfil gaps in
Companies: ALU WYN AFRN TSTL DXSP AEO HVO DXRX
Companies: ALU TSTL HVO FADL
5th June 2023 @HybridanLLP Status of this Note and Disclaimer This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectiv
Companies: IRON SRES TSTL GTC ORCP DXRX CEG VRCI
Companies: IOM FEN TSTL BBB KMK
Tristel received FDA clearance to market Tristel ULT as a high-level disinfectant (HLD) for use on endocavity ultrasound probes and skin surface transducers that may contact non-intact skin. This is a significant and arguably long-awaited, value-enhancing milestone for the company, enabling it to market DUO in the single largest ultrasound market in the world: a market with c.215m annual procedures and one that Tristel is very familiar with, given ultrasound accounts for c.50% of its annual reve
Research Tree provides access to ongoing research coverage, media content and regulatory news on Tristel Plc. We currently have 0 research reports from 7 professional analysts.
Share: